Integra LifeSciences develops medical technologies for surgery, tissue regeneration and specialty care. Its portfolio spans neurosurgery instruments and implants, regenerative tissue products, wound-care solutions and orthopedic reconstruction tools used in hospitals and surgical centers. The company is known for combining implantable biomaterials with specialized surgical devices for complex procedures. Customers are primarily surgeons, hospital systems and outpatient facilities in markets worldwide.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 382.6 | — | -25.3 | — |
| Q2 2025 | 415.6 | — | -484.1 | — |
| Q3 2025 | 402.1 | — | -5.4 | — |
| Q4 2025 | 434.9 | — | -1.7 | — |
| Q1 2026 | 391.9 | 2.4% | -4.6 | — |
| Q2 2026 | 418.8 | 0.8% | 4.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Immatics N.V. (IMTX), Critical Metals Corp. (CRML), Replimune Group, Inc. (REPL), Harrow, Inc. (HROW), Oaktree Specialty Lending Corporation (OCSL), Business First Bancshares, Inc. (BFST)